Literature DB >> 24022692

Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.

Joachim Rudolf Göthert, Lewin Eisele, Ludger Klein-Hitpass, Stefanie Weber, Marie-Louise Zesewitz, Ludger Sellmann, Alexander Röth, Hanspeter Pircher, Ulrich Dührsen, Jan Dürig.   

Abstract

Altered numbers and functions of T cells have previously been demonstrated in chronic lymphocytic leukemia (CLL) patients. However, dynamics and specific T-cell subset alterations have not been studied in great detail. Therefore, we studied CLL blood lymphocyte subsets of individual patients in a longitudinal manner. Dynamic expansions of blood CD4 + and CD8 + T-cell numbers were consistently associated with a progressively increasing CLL leukemic compartment. Interestingly, the T-cell subset expansion over time was more pronounced in CD38 + CLL. Additionally, we performed gene expression profiling of CD3 + T cells of CLL patients and normal donors. Using gene set enrichment analysis, we found significant enrichment of genes with higher expression in CLL T cells within CD8+ effector memory and terminal effector T-cell gene signatures. In agreement with these data, we observed a marked expansion of phenotypic CD8 + effector memory T cells in CLL by flow cytometry. Moreover, we observed that increments of CD8 + effector memory T cells in human CLL and also mouse CLL (Eμ-TCL1 model) were due to an expansion of the inhibitory killer cell lectin-like receptor G1 (KLRG1) expressing cellular subset. Furthermore, higher plasma levels of the natural KLRG1 ligand E-cadherin were detected in CLL patients compared to normal donor controls. The predominance of KLRG1+ expression within CD8+ T cells in conjunction with increased systemic soluble E-cadherin might significantly contribute to CLL immune dysfunction and might additionally represent an important component of the CLL microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24022692     DOI: 10.1007/s00262-013-1473-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Bypassing T cell 'exhaustion'.

Authors:  Joachim R Göthert
Journal:  Nat Immunol       Date:  2013-11       Impact factor: 25.606

2.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 3.  Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors:  Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2017-09-26

4.  Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Authors:  Lionel Apetoh; Mark J Smyth; Charles G Drake; Jean-Pierre Abastado; Ron N Apte; Maha Ayyoub; Jean-Yves Blay; Marc Bonneville; Lisa H Butterfield; Anne Caignard; Chiara Castelli; Federica Cavallo; Esteban Celis; Lieping Chen; Mario P Colombo; Begoña Comin-Anduix; Georges Coukos; Madhav V Dhodapkar; Glenn Dranoff; Ian H Frazer; Wolf-Hervé Fridman; Dmitry I Gabrilovich; Eli Gilboa; Sacha Gnjatic; Dirk Jäger; Pawel Kalinski; Howard L Kaufman; Rolf Kiessling; John Kirkwood; Alexander Knuth; Roland Liblau; Michael T Lotze; Enrico Lugli; Francesco Marincola; Ignacio Melero; Cornelis J Melief; Thorsten R Mempel; Elizabeth A Mittendorf; Kunle Odun; Willem W Overwijk; Anna Karolina Palucka; Giorgio Parmiani; Antoni Ribas; Pedro Romero; Robert D Schreiber; Gerold Schuler; Pramod K Srivastava; Eric Tartour; Danila Valmori; Sjoerd H van der Burg; Pierre van der Bruggen; Benoît J van den Eynde; Ena Wang; Weiping Zou; Theresa L Whiteside; Daniel E Speiser; Drew M Pardoll; Nicholas P Restifo; Ana C Anderson
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

5.  Genotype-phenotype correlation of T-cell subtypes reveals senescent and cytotoxic genes in Alzheimer's disease.

Authors:  Dallin Dressman; Thomas Buttrick; Maria Cimpean; David Bennett; Vilas Menon; Elizabeth M Bradshaw; Badri Vardarajan; Wassim Elyaman
Journal:  Hum Mol Genet       Date:  2022-09-29       Impact factor: 5.121

6.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 7.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

8.  Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.

Authors:  Jiazhu Wu; Xiaojing Xu; Eun-Joon Lee; Austin Y Shull; Lirong Pei; Farrukh Awan; Xiaoling Wang; Jeong-Hyeon Choi; Libin Deng; Hong-Bo Xin; Wenxun Zhong; Jinhua Liang; Yi Miao; Yujie Wu; Lei Fan; Jianyong Li; Wei Xu; Huidong Shi
Journal:  Oncotarget       Date:  2016-06-28

9.  Exploring the nature of prediagnostic blood transcriptome markers of chronic lymphocytic leukemia by assessing their overlap with the transcriptome at the clinical stage.

Authors:  Jelle Vlaanderen; Max Leenders; Marc Chadeau-Hyam; Lützen Portengen; Soterios A Kyrtopoulos; Ingvar A Bergdahl; Ann-Sofie Johansson; Dennie D G A J Hebels; Theo M C M de Kok; Paolo Vineis; Roel C H Vermeulen
Journal:  BMC Genomics       Date:  2017-03-20       Impact factor: 3.969

10.  Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.

Authors:  Joachim R Göthert; Roze Imsak; Michael Möllmann; Stefanie Kesper; Maria Göbel; Ulrich Dührsen; Arne Scholz; Ulrich Lücking; Matthias Baumann; Anke Unger; Carsten Schultz-Fademrecht; Bert Klebl; Jan Eickhoff; Axel Choidas; Jan Dürig
Journal:  Oncotarget       Date:  2018-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.